Why is there so little real-world evidence for botanical protocols?

Mainly because practice data is unstructured: protocols vary by practitioner and are rarely documented in comparable form, outcomes are seldom captured systematically, and follow-up is inconsistent. Evidence requires consistent capture of who received what, why, and what happened next — most botanical practice today doesn't record this in an aggregatable way.

What must a clinic document for its data to count toward RWE?

At minimum: a structured baseline (intake), the protocol actually used (ingredients, form, dose, duration), the rationale, adherence, objective and patient-reported outcomes on a fixed schedule, and any adverse events. The same structure must be used across patients and clinics for data to be aggregated.

Does real-world evidence replace randomized controlled trials?

No. RWE complements RCTs. It can characterize how care performs in routine practice and generate hypotheses, and regulators increasingly accept it in defined contexts, but randomized trials remain the standard for establishing efficacy.

For clinicians

Real-world evidence for botanical protocols: what it actually takes

Q: What is real-world evidence (RWE)?

Real-world evidence is clinical evidence about the usage, benefits, or risks of a medical product derived from real-world data — data collected outside conventional randomized trials, such as records from routine care, registries, and patient-generated data including wearables. The FDA formalized its RWE program after the 21st Century Cures Act of 2016.

By the tcm.ai Clinical Team · Published July 8, 2026

Direct answer

Real-world evidence (RWE) for botanical protocols requires what most botanical practice currently lacks: consistent, structured documentation of who received which protocol, why, at what dose and duration, with outcomes captured on a fixed schedule. The gap is not clinical experience — decades of it exist — but data structure. Clinics that standardize intake, protocol records, and follow-up can convert routine practice into aggregatable, benchmarkable real-world data.

Key facts

Real-world data (RWD) is health data collected outside conventional trials (routine care records, registries, wearables); real-world evidence (RWE) is the clinical evidence derived from analyzing it (FDA definitions).
The FDA's RWE program was mandated by the 21st Century Cures Act (2016), and its RWE framework was published in 2018 — real-world data is now an accepted evidence category in defined regulatory contexts.
Patient-generated data, including CGM and other wearables, is explicitly recognized by FDA as a real-world data source.
36.7% of US adults used complementary health approaches in 2022 (JAMA, 2024) — a large, growing population whose botanical care generates almost no structured outcome data today.

The paradox: enormous experience, thin evidence

Botanical and TCM protocols carry centuries of accumulated clinical experience and decades of individual practitioner expertise. Yet in evidence terms this experience is nearly invisible: it lives in narrative notes, varies practitioner to practitioner, and is almost never captured with the consistency that aggregation requires. The result is a systematic mismatch — high clinical conviction, low usable evidence — that limits research, integration with mainstream care, and ultimately patient access.

What "structured enough for evidence" means

For practice data to become real-world evidence, five things must be documented the same way for every patient, every cycle:

Baseline: a structured intake — in TCM settings, the four examinations and pattern assessment in defined fields, plus relevant metabolic markers.
Exposure: the protocol actually used — ingredients, form, dose, duration, and modifications. "Custom formula" as free text cannot be aggregated; a formula recorded as structured components can.
Rationale: the pattern or indication the protocol targeted, so responders can later be characterized.
Outcomes on a schedule: objective measures (for metabolic care, CGM metrics such as time in range are natural candidates) and patient-reported outcomes at fixed intervals — not only when the patient happens to return.
Safety: adverse events and tolerability, recorded even when absent ("none observed" is data).

Why networks beat single clinics

A single clinic documenting well produces a case series. A network of clinics documenting identically produces a dataset: sample sizes large enough to see patterns across constitutions, protocols, and time. This is why shared workflow infrastructure matters more than any individual clinic's diligence — the structure must be common, or the data won't pool. Building that common structure across US integrative clinics is the explicit goal of tcm.ai's evidence network.

Honest limits

RWE from practice data has known constraints: no randomization, selection effects, confounding by lifestyle changes made alongside protocols. It complements rather than replaces randomized trials. But the choice facing botanical practice today is not RWE versus RCTs — it is structured data versus no data. Structure is the step that makes every later form of evidence possible.

FAQ

What is real-world evidence (RWE)?

Clinical evidence about usage, benefits, or risks derived from real-world data — data collected outside conventional trials, such as routine care records, registries, and wearable data. The FDA formalized its RWE program after the 21st Century Cures Act (2016).

Why is there so little RWE for botanical protocols?

Because practice data is unstructured: protocols and outcomes are rarely documented in comparable form. Evidence requires consistent capture of who received what, why, and what happened next.

What must a clinic document for its data to count?

Structured baseline, the exact protocol (components, dose, duration), rationale, adherence, scheduled objective and patient-reported outcomes, and adverse events — in the same structure across patients and clinics.

Does RWE replace randomized controlled trials?

No — it complements them. RWE characterizes routine-practice performance and generates hypotheses; RCTs remain the standard for establishing efficacy.

Sources

FDA. Real-World Evidence (program overview and framework).
21st Century Cures Act, Pub. L. 114-255 (2016).
Nahin RL, et al. Use of Complementary Health Approaches Overall and for Pain Management by US Adults. JAMA. 2024.

More from tcm.ai Learn

tcm.ai is building the shared documentation structure that lets integrative clinics turn botanical practice into real-world evidence.

Apply as a Pilot Clinic →

This article is educational and intended for clinicians. It is not medical advice, and it makes no efficacy claims about any botanical protocol. tcm.ai does not diagnose, treat, cure, or prevent any disease.